

# User Manual

Fibroblast Growth Factor-23 (FGF-23) (Human) Cat. No. HEGFP-06233





# **Description:**

Fibroblast growth factor-23 (FGF-23) belongs to the large FGF family which has at least 23 members. All FGF family members are heparin binding growth factors with a core 120 amino acid (a.a.) FGF domain that allows for a common tertiary structure. FGFs are expressed during embryonic development and in restricted adult tissues. Four distinct but related classes of FGF receptors, FGF R1, 2, 3, and 4 exist. FGF-23 is produced by osteocytes and osteoblasts in response to high circulating phosphate levels, elevated parathyroid hormone, and circulatory volume loading. It functions as an endocrine phosphatonin by suppressing circulating phosphate levels. FGF-23 interaction with renal proximal tubular epithelium decreases the renal resorption of phosphate by down regulating phosphate transporters and by suppressing vitamin D production. It also decreases the intestinal absorption of phosphate.

#### Source:

Escherichia coli

#### **Unit:**

1 mg

### **Reconstitution:**

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20°C. Further dilutions should be made in appropriate buffered solutions.

#### Formulation:

Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.

## Storage:

This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working



aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.

## **Molecular Weight:**

Approximately 25.4 kDa, a single non-glycosylated polypeptide chain containing 227 amino acids.

## **Endotoxin:**

Less than 1 EU/µg of FGF-23 as determined by LAL method.

# **Usage:**

This material is offered by Cyagen Biosciences for research, laboratory or further evaluation purposes. FOR RESEARCH USE ONLY. NOT INTENDED FOR ANY ANIMAL OR HUMAN THERAP EUTIC OR DIAGNOSTIC USE.

# **Biological Activity:**

The ED50 determined by a cell proliferation assay using murine NIH/3T3 cells is less than 300 ng/mL, corresponding to a specific activity of >  $3.3 \times 10^3$  IU/mg in the presence of 5  $\mu$ g/mL of Klotho and 10  $\mu$ g/mL of heparin.

## **Physical Appearance:**

Sterile filtered white lyophilized (freeze-dried) powder.

# **AA Sequence:**

YPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI PRRHTRSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP LGVVRGGRVN THAGGTGPEG CRPFAKFI

## **Purity:**

> 95% by SDS-PAGE and HPLC analyses.



Material Safety Data Sheets (MSDSs) are available upon request.

The Certificate of Analysis (COA), which provides detailed quality control information for each product, is also available at the Cyagen website.

Cyagen Biosciences reserves all rights on the technical documents of its culture products. No part of this document may be reproduced or adapted for other purposes without written permission from Cyagen Biosciences.